Avastin®

DRUG5 trials

Sponsors

Retinal Consultants of Arizona, TRPHARM, Qilu Pharmaceutical Co., Ltd.

Conditions

HealthyNeovascular Age-Related Macular DegenerationNon Small Cell Lung CancerNon-squamous Non-small Cell Lung CancerTumor

Phase 1

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

CompletedNCT02591914

Retinal Consultants of ArizonaNeovascular Age-Related Macular Degeneration

Start: 2014-02-28End: 2016-05-24Updated: 2018-09-24

Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator

WithdrawnNCT03131700

Start: 2017-12-31End: 2018-01-31Updated: 2018-04-12

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

CompletedNCT06232902

Qilu Pharmaceutical Co., Ltd.Tumor

Start: 2024-06-20End: 2024-11-18Updated: 2024-12-18

Phase 3

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

CompletedNCT03169335

Qilu Pharmaceutical Co., Ltd.Non-squamous Non-small Cell Lung Cancer

Start: 2017-03-28End: 2018-07-13Updated: 2018-08-24

Unknown Phase

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Qilu Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2017-03-01End: 2018-12-10Target: 15Updated: 2017-06-22

Related Papers

A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology2019-04-014 citations